678 related articles for article (PubMed ID: 21624553)
1. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis.
Almalla M; Schröder JW; Pross V; Stegemann E; Marx N; Hoffmann R
Am J Cardiol; 2011 Aug; 108(4):518-22. PubMed ID: 21624553
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
3. Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.
Almalla M; Schröder JW; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2013 Mar; 24(2):165-70. PubMed ID: 23242011
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.
Mahmoudi M; Delhaye C; Wakabayashi K; Ben-Dor I; Gonzalez MA; Maluenda G; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Am J Cardiol; 2011 Jun; 107(12):1757-62. PubMed ID: 21497782
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
[TBL] [Abstract][Full Text] [Related]
6. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
8. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
10. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
Daemen J; Tanimoto S; García-García HM; Kukreja N; van de Sande M; Sianos G; de Jaegere PP; van Domburg RT; Serruys PW
Am J Cardiol; 2007 Apr; 99(8):1027-32. PubMed ID: 17437722
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
14. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial.
Violini R; Musto C; De Felice F; Nazzaro MS; Cifarelli A; Petitti T; Fiorilli R
J Am Coll Cardiol; 2010 Feb; 55(8):810-4. PubMed ID: 20170821
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis.
Ota H; Mahmoudi M; Torguson R; Satler LF; Suddath WO; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2015; 16(3):151-5. PubMed ID: 25977226
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.
Kitabata H; Loh JP; Pendyala LK; Badr S; Dvir D; Barbash IM; Minha S; Torguson R; Chen F; Satler LF; Suddath WO; Kent KM; Pichard AD; Waksman R
Am J Cardiol; 2013 Oct; 112(8):1093-8. PubMed ID: 23827397
[TBL] [Abstract][Full Text] [Related]
17. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
18. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
[TBL] [Abstract][Full Text] [Related]
19. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials.
Ito H; Hermiller JB; Yaqub M; Newman W; Sood P; Wang JC; Cannon L; Maddux JE; Sudhir K; Stone GW
J Interv Cardiol; 2011 Dec; 24(6):505-13. PubMed ID: 21919955
[TBL] [Abstract][Full Text] [Related]
20. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
